Last reviewed · How we verify
TPX-114
TPX-114 is a small molecule inhibitor of the CDK9 enzyme.
TPX-114 is a small molecule inhibitor of the CDK9 enzyme. Used for Relapsed or refractory diffuse large B-cell lymphoma, Relapsed or refractory follicular lymphoma.
At a glance
| Generic name | TPX-114 |
|---|---|
| Sponsor | Tego Science, Inc. |
| Drug class | CDK inhibitor |
| Target | CDK9 |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By inhibiting CDK9, TPX-114 reduces the phosphorylation of RNA polymerase II, leading to a decrease in mRNA transcription and subsequent reduction in protein synthesis. This mechanism is particularly relevant in the treatment of cancer, where uncontrolled cell growth is a hallmark of the disease.
Approved indications
- Relapsed or refractory diffuse large B-cell lymphoma
- Relapsed or refractory follicular lymphoma
Common side effects
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- A Phase I/III Clinical Study of TPX-114 for the Treatment of Full-Thickness Rotator Cuff Tear (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |